Regular paper
A third human tissue transglutaminase homologue as a result of alternative gene transcripts

https://doi.org/10.1016/0167-4781(95)00219-7Get rights and content

Abstract

A 2.4 kilobase (kb) cDrIA encoding a new form of human tissue transglutaminase homologue (TGH2) was isolated from retinoic acid-induced human erythroleukemia cell (HEL) library. Full-length cDNA analysis gives an open reading frame coding for a polypeptide of 349 amino acid residues with a molecular mass of 38 700 Da. This variant differs from the previously reported homologue TGH in that it is 199 amino acids shorter and has an alternative, 63 amino acid COOH-terminal peptide. The 3′-untranslated region of the cDNA also differs from the previously reported sequences for both TGH and human tissue transglutaminase. The region coding for the first 286 amino acids of TGH2, which contains the active site is identical to TGH. Immunoprecipitation of the in vitro translation product from a synthetic TGH2 mRNA and immunoprecipitation of total protein of human heart, liver, kidney and cultured erythroleukemia HEL cell, revealed a protein with a molecular mass of 37 000 Da by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Comparison of the cDNA sequences for the previously known tissue transglutaminases with genomic DNA and the TGH2 cDNA described here indicate that the sequence divergence points correlate with known intron-exon boundaries. The smaller RNA species encode for truncated proteins with novel carboxyl termini. The TGH cDNA and the TGH2 cDNA both produce transcripts which start with the regular coding sequence for TGase and then fail to splice at specific donor sites, resulting in the use of an alternative exon that contains a stop codon.

References (49)

  • S. Matacic et al.

    Biochem. Biophys. Res. Commun.

    (1968)
  • L. Fesus et al.

    FEBS Lett.

    (1987)
  • C.R.L. Knight et al.

    Biochim. Biophys. Acta

    (1991)
  • J.Y. Wang et al.

    Am. J. Physiol.

    (1993)
  • S.M. Thacher et al.

    Cell

    (1985)
  • H.C. Kim et al.

    J. Biol. Chem.

    (1990)
  • V. Gentile et al.

    J. Biol. Chem.

    (1991)
  • B.M. Fraij et al.

    J. Biol. Chem.

    (1992)
  • Y. Takeuchi et al.

    FEBS

    (1992)
  • R.M. Stephens et al.

    J. Mol. Biol.

    (1992)
  • G. Shaw et al.

    Cell

    (1986)
  • S. Nagpal et al.

    Cell

    (1992)
  • J.E. Folk et al.

    J. Biol. Chem.

    (1966)
  • M.M. Buxman et al.

    Biochim. Biophys. Acta.

    (1976)
  • S.I. Chung et al.

    J. Biol. Chem.

    (1974)
  • A. Ichinose et al.

    J. Biol. Chem.

    (1990)
  • R.T. Dell'Orco et al.

    Cell Biol. Inter. Rep.

    (1985)
  • K.N. Lee et al.

    Biochim. Biophys. Acta

    (1993)
  • J.E. Folk et al.

    Adv. Enzymol.

    (1973)
  • C.S. Greenberg et al.

    FASEB J.

    (1991)
  • L. Lorand et al.
  • L.L. Peterson et al.

    Mol. Cell. Biochem.

    (1984)
  • P.J. Bungay et al.

    Biochem. J.

    (1986)
  • P.J.A. Davies et al.

    Nature

    (1980)
  • Cited by (29)

    • Transglutaminase 2 as a novel target in chronic kidney disease – Methods, mechanisms and pharmacological inhibition

      2021, Pharmacology and Therapeutics
      Citation Excerpt :

      Additionally, a third splicing variant was identified in human kidney tissue, named TGH2, with unknown function. TGH2 is different from TGH in the calcium-binding site, which is missing in TGH2 (Fraij & Gonzales, 1996). Stimulation of renal proximal tubular epithelial or HUVEC cell lines with high glucose concentrations increased TG2 expression and activity (Bhatt et al., 2013; Furini et al., 2020; Skill et al., 2004).

    • Transglutaminase 2: A molecular Swiss army knife

      2012, Biochimica et Biophysica Acta - Molecular Cell Research
      Citation Excerpt :

      Very intriguingly, several stress conditions and inducers have been shown to result in the expression of different isoforms of TG2 [34,95–99]. In response to retinoic acid [95,96] and cytokines [99] different splice variants were observed in different models. Similarly, central nervous system pathologies such as Alzheimer disease [97] and acute spinal cord injury [98] caused upregulation of certain isoforms.

    • Cellular Functions of Tissue Transglutaminase

      2012, International Review of Cell and Molecular Biology
      Citation Excerpt :

      Finally, tTGV1 and tTGV2 variants were identified in vascular smooth muscle cells, endothelial cells, and leukocytes and were found to be identical to TG2 in their initial 622 amino acids, but had divergent C-termini of 52 and 23 amino acids, respectively (Lai et al., 2007). With the clear exception of the shortest isoform which has to be inactive because it is missing a part of the catalytic triad (Fraij and Gonzales, 1996), all other currently described TG2 isoforms should retain transamidating activity. Given that their truncated or divergent C-termini lack either some parts or the entire GTP-binding pocket, their transamidating activity is not expected to be repressed even by high intracellular GTP levels, making them more sensitive to Ca2 + activation and catalytically active under physiological conditions.

    • Intron-Exon Swapping of Transglutaminase mRNA and Neuronal Tau Aggregation in Alzheimer's Disease

      2001, Journal of Biological Chemistry
      Citation Excerpt :

      In contrast, in AD cortex, but not in the aged, non-demented brain, we found evidence for variant tTG messages (Fig. 7). This human AD short tTG mRNA results from alternative splicing at the same position (Fig. 8), involving a substitution immediately after amino acid residue 538, previously observed in human erythroleukemia (HEL) cells (57). In one case (Fig. 8, italics) a slight variation in the splicing event resulted in a different coding frame which also terminated within 60 bases of the junction.

    View all citing articles on Scopus
    View full text